<?xml version="1.0" encoding="UTF-8"?>
<p>On 1 June 2020, Gilead Sciences, Inc. announced the results obtained from SIMPLE trial 2, as follows: (i) the 5-day treatment with RDV led to a significant improved clinical status in patients with moderate COVID-19 symptomatology at day 11 as compared with standard care group (in 65% of patients); and (ii) in terms of safety and adverse effects noticed, RDV treatment was well tolerated and the most common adverse effects observed were nausea (10% of the patients), diarrhea (5%), and headache (5% of the patients), and no deaths were recorded as compared with the standard care group that enlisted four deaths [
 <xref rid="B74-jcm-09-02084" ref-type="bibr">74</xref>]. In addition, since 7 May 2020, Remdesivir (Veklury
 <sup>Â®</sup>) was approved in Japan as a treatment for patients with severe COVID-19 pathology [
 <xref rid="B75-jcm-09-02084" ref-type="bibr">75</xref>].
</p>
